United States Securities and Exchange Commission · EDGAR Accession 0001957114-26-000001

Form C-AR

Annual Report — Regulation Crowdfunding
Issuer CIK 1957114
Period 2025-12-31

iMetabolic Biopharma Corporation

CorporationNVIncorporated 2017Phoenix, AZimbiopharma.com
B

Financial Condition

two fiscal years, as filed
Revenue +6% YoYBurn decreasingDebt / assets 2243%4 employees
Line itemMost recent FYPrior FYΔ
Revenue137,329129,520▲ 6%
Cost of goods sold00
Net income(99,746)(120,292)▲ burn
Total assets27,78782,459▼ 66%
Cash & equivalents25,72682,459▼ 69%
Accounts receivable20
Short-term debt65,37847,853▲ 37%
Long-term debt557,7790
Taxes paid00

Figures in USD as reported by the issuer.